{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:17:05Z","timestamp":1794557825795,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370657"],"award-info":[{"award-number":["81370657"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470328"],"award-info":[{"award-number":["81470328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014207","name":"the National Public Health Grand Research Foundation","doi-asserted-by":"crossref","award":["201202017"],"award-info":[{"award-number":["201202017"]}],"id":[{"id":"10.13039\/501100014207","id-type":"DOI","asserted-by":"crossref"}]},{"name":"a project funded by the Priority Academic Programme Development of Jiangsu Higher Education Institute","award":["JX10231801"],"award-info":[{"award-number":["JX10231801"]}]},{"name":"a project funded by Jiangsu Provincial Special Programme of Medical Science","award":["BL2014086"],"award-info":[{"award-number":["BL2014086"]}]},{"name":"Key Projects of the Health Department of Jiangsu Province","award":["K201108"],"award-info":[{"award-number":["K201108"]}]},{"name":"Jiangsu Province\u2019s Medical Elite Programme","award":["RC2011169"],"award-info":[{"award-number":["RC2011169"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0267-0","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T11:34:31Z","timestamp":1460633671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Therapeutic options in peripheral T cell lymphoma"],"prefix":"10.1186","volume":"9","author":[{"given":"Yaping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"267_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. France: IARC Press; 2008.","edition":"4"},{"issue":"25","key":"267_CR2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"6","key":"267_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrclinonc.2011.51","volume":"8","author":"F Foss","year":"2011","unstructured":"Foss F. Hematology: relapsed and refractory PTCL\u2014into the therapeutic abyss. Nat Rev Clin Oncol. 2011;8(6):321\u20132.","journal-title":"Nat Rev Clin Oncol"},{"key":"267_CR4","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.","journal-title":"ISRN Hematol"},{"issue":"18","key":"267_CR5","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"1","key":"267_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2013.11.001","volume":"51","author":"L Karlin","year":"2014","unstructured":"Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25\u201334.","journal-title":"Semin Hematol"},{"key":"267_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin\u2019s lymphoma, V.2.2015. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 23 March 2015."},{"issue":"6","key":"267_CR8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","volume":"54","author":"L Marquard","year":"2009","unstructured":"Marquard L, Poulsen CB, Gjerdrum LM, de Nully BP, Christensen IJ, Jensen PB, Sehested M, Johansen P, Ralfkiaer E. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009;54(6):688\u201398.","journal-title":"Histopathology"},{"issue":"22","key":"267_CR9","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827\u201334.","journal-title":"Blood"},{"issue":"6","key":"267_CR10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"key":"267_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.","journal-title":"J Hematol Oncol"},{"key":"267_CR12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-7771-2-16","volume":"2","author":"F Foss","year":"2014","unstructured":"Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma. Biomark Res. 2014;2:16.","journal-title":"Biomark Res"},{"issue":"1","key":"267_CR13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","volume":"9","author":"F Foss","year":"2016","unstructured":"Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9(1):22.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"267_CR14","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Bras FL, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol. 2015;2(4):e160\u20135.","journal-title":"Lancet Haematol"},{"issue":"15_Suppl","key":"267_CR15","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/jco.2013.31.15_suppl.8507","volume":"31","author":"OA O\u2019Connor","year":"2013","unstructured":"O\u2019Connor OA, Masszi T, Savage KJ. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): Results from the BELIEF trial. J Clin Oncol (ASCO Meeting Abstact). 2013;31(15_Suppl):8507.","journal-title":"J Clin Oncol (ASCO Meeting Abstact)"},{"issue":"23","key":"267_CR16","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015;33(23):2492\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"267_CR17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811\u20139.","journal-title":"Br J Haematol"},{"key":"267_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jchromb.2015.07.001","volume":"1000","author":"R Gu","year":"2015","unstructured":"Gu R, Liu T, Zhu X, Gan H, Wu Z, Li J, Zheng Y, Dou G, Meng Z. Development and validation of a sensitive HPLC-MS\/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1000:181\u20136.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"8","key":"267_CR19","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766\u201371.","journal-title":"Ann Oncol"},{"issue":"18","key":"267_CR20","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190\u20136.","journal-title":"J Clin Oncol"},{"issue":"20","key":"267_CR21","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095\u2013100.","journal-title":"Blood"},{"issue":"28","key":"267_CR22","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137\u201343.","journal-title":"J Clin Oncol"},{"issue":"9","key":"267_CR23","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"267_CR24","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00277-013-1880-4","volume":"92","author":"C Binder","year":"2013","unstructured":"Binder C, Ziepert M, Pfreundschuh M, Duhrsen U, Eimermacher H, Aldaoud A, Rosenwald A, Loeffler M, Schmitz N, Truemper L. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol. 2013;92(11):1521\u20138.","journal-title":"Ann Hematol"},{"issue":"3","key":"267_CR25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/10428190903580402","volume":"51","author":"E Weidmann","year":"2010","unstructured":"Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jager E, Mitrou PS. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. Leuk Lymphoma. 2010;51(3):447\u201355.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"267_CR26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837\u201342.","journal-title":"J Clin Oncol"},{"issue":"11","key":"267_CR27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363.","journal-title":"J Clin Oncol"},{"issue":"5","key":"267_CR28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","volume":"150","author":"F d\u2019Amore","year":"2010","unstructured":"d\u2019Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol. 2010;150(5):565\u201373.","journal-title":"Br J Haematol"},{"issue":"19","key":"267_CR29","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","volume":"116","author":"G Dueck","year":"2010","unstructured":"Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, van der Jagt R, Johnston J, Belch A, Reiman T. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer. 2010;116(19):4541\u20138.","journal-title":"Cancer"},{"issue":"13","key":"267_CR30","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49(13):2869\u201376.","journal-title":"Eur J Cancer"},{"issue":"5","key":"267_CR31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","volume":"121","author":"E Toumishey","year":"2015","unstructured":"Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt R, Stewart D, White D, Belch A, Reiman T. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716\u201323.","journal-title":"Cancer"},{"issue":"4","key":"267_CR32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860\u20133.","journal-title":"Ann Oncol"},{"issue":"11","key":"267_CR33","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","volume":"94","author":"BB Park","year":"2015","unstructured":"Park BB, Kim WS, Suh C, Shin DY, Kim JA, Kim HG, Lee WS. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015;94(11):1845\u201351.","journal-title":"Ann Hematol"},{"issue":"27","key":"267_CR34","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","volume":"25","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293\u20137.","journal-title":"J Clin Oncol"},{"issue":"17","key":"267_CR35","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","volume":"48","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS. Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48(17):3223\u201331.","journal-title":"Eur J Cancer"},{"issue":"1","key":"267_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.12488","volume":"163","author":"AM Evens","year":"2013","unstructured":"Evens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, van Besien KM, Gordon LI, Smith SM. A phase I\/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. Br J Haematol. 2013;163(1):55\u201361.","journal-title":"Br J Haematol"},{"issue":"5","key":"267_CR37","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/modpathol.2012.211","volume":"26","author":"R Kanagal-Shamanna","year":"2013","unstructured":"Kanagal-Shamanna R, Lehman NL, O\u2019Donnell JP, Lim MS, Schultz DS, Chitale DA, Bueso-Ramos CE, Medeiros LJ, Inamdar KV. Differential expression of aurora-A kinase in T-cell lymphomas. Mod Pathol. 2013;26(5):640\u20137.","journal-title":"Mod Pathol"},{"issue":"1","key":"267_CR38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","volume":"32","author":"JW Friedberg","year":"2014","unstructured":"Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32(1):44\u201350.","journal-title":"J Clin Oncol"},{"issue":"21","key":"267_CR39","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","volume":"33","author":"PM Barr","year":"2015","unstructured":"Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33(21):2399\u2013404.","journal-title":"J Clin Oncol"},{"issue":"2","key":"267_CR40","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","volume":"106","author":"C Gambacorti Passerini","year":"2014","unstructured":"Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L, Piazza R. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):djt378.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"267_CR41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","volume":"31","author":"G Damaj","year":"2013","unstructured":"Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Bene MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31(1):104\u201310.","journal-title":"J Clin Oncol"},{"issue":"22","key":"267_CR42","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.2169\/internalmedicine.49.4083","volume":"49","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Ikejiri F, Onishi C, Kawakami K, Inoue M, Miyake T, Tanaka J, Araki A, Maruyama R, Ohshima K, Suzumiya J. L-asparaginase-induced complete response in a relapsed patient with Epstein-Barr virus and cytotoxic peripheral T-cell lymphoma not otherwise specified. Intern Med. 2010;49(22):2505\u20138.","journal-title":"Intern Med"},{"issue":"6","key":"267_CR43","first-page":"9374","volume":"8","author":"G Yao","year":"2015","unstructured":"Yao G, Zhou D, Zhou M, Bao C, He D, Li L, Zhu J, He J, Shi J, Zheng W, Cai Z, Huang H, Ye X, Xie W. Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma. Int J Clin Exp Med. 2015;8(6):9374\u201383.","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"267_CR44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","volume":"126","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, Gupta M. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126(3):328\u201335.","journal-title":"Blood"},{"issue":"15","key":"267_CR45","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741\u201352.","journal-title":"Blood"},{"issue":"6","key":"267_CR46","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.13170","volume":"168","author":"M Cheminant","year":"2015","unstructured":"Cheminant M, Bruneau J, Kosmider O, Lefrere F, Delarue R, Gaulard P, Radford I, Derrieux C, Hermine O, Lemonnier F. Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol. 2015;168(6):913\u20136.","journal-title":"Br J Haematol"},{"issue":"25","key":"267_CR47","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Osterborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Ostenstad B, Fagerli UM, Gadeberg OV, Sundstrom C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"267_CR48","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","volume":"21","author":"A Beitinjaneh","year":"2015","unstructured":"Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, Fayad L, Fanale MA, Alousi AM, Anderlini P, Betul O, Popat UR, Pro B, Khouri IF. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"267_CR49","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2011-02-334904","volume":"118","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011;118(18):4882\u20139.","journal-title":"Blood"},{"issue":"1","key":"267_CR50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajh.22232","volume":"87","author":"PJ Hosein","year":"2012","unstructured":"Hosein PJ, Craig MD, Tallman MS, Boccia RV, Hamilton BL, Lewis JJ, Lossos IS. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Am J Hematol. 2012;87(1):111\u20134.","journal-title":"Am J Hematol"},{"issue":"2","key":"267_CR51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","volume":"49","author":"M Duvic","year":"2013","unstructured":"Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbe C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386\u201394.","journal-title":"Eur J Cancer"},{"issue":"4","key":"267_CR52","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clml.2013.02.020","volume":"13","author":"M Duvic","year":"2013","unstructured":"Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013;13(4):377\u201384.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"267_CR53","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1038\/bcj.2014.71","volume":"4","author":"SE Assouline","year":"2014","unstructured":"Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui AM, Yu J, Gupta N, Di Bacco A, Shou Y, Martin P. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed\/refractory lymphoma. Blood Cancer J. 2014;4:e251.","journal-title":"Blood Cancer J"},{"issue":"1","key":"267_CR54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.12944","volume":"167","author":"JF Gibson","year":"2014","unstructured":"Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. Br J Haematol. 2014;167(1):141\u20134.","journal-title":"Br J Haematol"},{"issue":"9","key":"267_CR55","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdu231","volume":"25","author":"R Dummer","year":"2014","unstructured":"Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Ann Oncol. 2014;25(9):1807\u201312.","journal-title":"Ann Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0267-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T17:31:27Z","timestamp":1600450287000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-016-0267-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0267-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]},"article-number":"37"}}